Jonas Sjölund

Jonas Sjölund

Auto-generated profile, based on publicly available information

Jonas Sjölund

Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University Cancer Centre, Lund University, Lund, Sweden

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2011 in The American Journal of Pathology
Verified
Journal Article
Closed access
DLDavid Lindgren
David Lindgren
ABAnna-Karin Boström
Anna-Karin Boström
KNKristina Nilsson
Kristina Nilsson
JHJennifer Hansson
Jennifer Hansson
JSJonas Sjölund
Jonas Sjölund
MJMartin Eugen Johansson
Martin Eugen Johansson

2 January 2008 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
JSJonas Sjölund
Jonas Sjölund
MJMartin Johansson
Martin Johansson
SMSugata Manna
Sugata Manna
CNCarl Norin
Carl Norin
APAlexander Pietras
Alexander Pietras
HAHakan Axelson
Hakan Axelson
Loss of the tumor suppressor gene von Hippel–Lindau (VHL) plays a key role in the oncogenesis of clear cell renal cell carcinoma (CCRCC). The loss leads to stabilization of the HIF transcription complex, which induces angiogenic and mitogenic pathways essential for tumor formation. Nonetheless, additional oncogenic events have been postulated to be required for the formation of CCRCC tumors. Here, we show that the Notch signaling cascade is constitutively active in human CCRCC cell lines independently of the VHL/HIF pathway. Blocking Notch signaling resulted in attenuation of proliferation and restrained anchorage-independent growth of CCRCC cell lines. Using siRNA targeting the different Notch receptors established that the growth-promoting effects of the Notch signaling pathway were attributable to Notch-1 and that Notch-1 knockdown was accompanied by elevated levels of the negative cell-cycle regulators p21Cip1 and/or p27Kip1. Treatment of nude mice with an inhibitor of Notch signaling potently inhibited growth of xenotransplanted CCRCC cells. Moreover, Notch-1 and the Notch ligand Jagged-1 were expressed at significantly higher levels in CCRCC tumors than in normal human renal tissue, and the growth of primary CCRCC cells was attenuated upon inhibition of Notch signaling. These findings indicate that the Notch cascade may represent a novel and therapeutically accessible pathway in CCRCC.

12 March 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
PRPernilla Roswall
Pernilla Roswall
MBMatteo Bocci
Matteo Bocci
MBMichael Bartoschek
Michael Bartoschek
HLHong Li
Hong Li
GKGlen Kristiansen
Glen Kristiansen
KPKristian Pietras
Kristian Pietras

29 September 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
APAlexander Pietras
Alexander Pietras
LHLoen M. Hansford
Loen M. Hansford
AJA. Sofie Johnsson
A. Sofie Johnsson
EBEsther Bridges
Esther Bridges
JSJonas Sjölund
Jonas Sjölund
SPSven Påhlman
Sven Påhlman
High hypoxia-inducible factor-2α (HIF-2α) protein levels predict poor outcome in neuroblastoma, and hypoxia dedifferentiates cultured neuroblastoma cells toward a neural crest-like phenotype. Here, we identify HIF-2α as a marker of normoxic neural crest-like neuroblastoma tumor-initiating/stem cells (TICs) isolated from patient bone marrows. Knockdown of HIF-2α reduced VEGF expression and induced partial sympathetic neuronal differentiation when these TICs were grown in vitro under stem cell-promoting conditions. Xenograft tumors of HIF-2α-silenced cells were widely necrotic, poorly vascularized, and resembled the bulk of tumor cells in clinical neuroblastomas by expressing additional sympathetic neuronal markers, whereas control tumors were immature, well-vascularized, and stroma-rich. Thus, HIF-2α maintains an undifferentiated state of neuroblastoma TICs. Because low differentiation is associated with poor outcome and angiogenesis is crucial for tumor growth, HIF-2α is an attractive target for neuroblastoma therapy.

1 February 2005 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
MSM-T Stockhausen
M-T Stockhausen
JSJ Sjölund
J Sjölund
CMC Manetopoulos
C Manetopoulos
HAH Axelson
H Axelson
Neuroblastoma (NB), a sympathetically derived childhood tumour, shows characteristics of neuronal precursor cells, suggesting a halted differentiation process. We have previously shown that the Notch signalling cascade, a key player during normal neurogenesis, also might be involved in NB differentiation. Valproic acid (VPA), a well-tolerated antiepileptic drug, has been shown to induce differentiation and cell death of NB cells, possibly associated with its recently described HDAC inhibiting activity. Stimulation of NB cells with VPA led to increased cell death and phenotypic changes associated with differentiation, that is, neurite extension and upregulation of neuronal markers. VPA treatment also led to an activated Notch signalling cascade as shown by increased levels of intracellular Notch-1 and Hes-1, mimicking the initial phase of induced differentiation. These results reinforce that VPA potentially could be used in differentiation therapy of NB and that the effects in part could be a consequence of interference with the Notch signalling cascade.

1 November 2005 in European Journal of Cancer
Verified
Journal Article
Closed access
JSJonas Sjölund
Jonas Sjölund
CMChristina Manetopoulos
Christina Manetopoulos
MSMarie-Thérése Stockhausen
Marie-Thérése Stockhausen
HAHåkan Axelson
Håkan Axelson